Considering the Potential for Gene-Based Therapy in Prostate Cancer

Evaluation of research and clinical trials in gene therapy reveals a concentration of activity in prostate cancer research and practice.
[Nature Reviews Urology]
Gregg, J. R., & Thompson, T. C. (2021). Considering the potential for gene-based therapy in prostate cancer. Nature Reviews Urology, 1–15. https://doi.org/10.1038/s41585-021-00431-x Cite
Abstract
Bookmark

No account yet? Register

0
Share

LONP1 and ClpP Cooperatively Regulate Mitochondrial Proteostasis for Cancer Cell Survival

Researchers identified functional crosstalk between LONP1 and ClpP, two mitochondrial matrix proteases that cooperate to attenuate proteotoxic stress and protect mitochondrial functions for cancer cell survival.
[Oncogenesis]
Lee, Y. G., Kim, H. W., Nam, Y., Shin, K. J., Lee, Y. J., Park, D. H., Rhee, H.-W., Seo, J. K., & Chae, Y. C. (2021). LONP1 and ClpP cooperatively regulate mitochondrial proteostasis for cancer cell survival. Oncogenesis, 10(2), 1–14. https://doi.org/10.1038/s41389-021-00306-1 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Anti-Tumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Combination treatment with NLG207, a nanoparticle-drug conjugate of camptothecin and inhibitor of HIF-1α, and enzalutamide was evaluated in preclinical prostate cancer models of enzalutamide resistance.
[Molecular Cancer Therapeutics]
Schmidt, K. T., Chau, C. H., Strope, J. D., Huitema, A. D. R., Sissung, T. M., Price, D. K., & Figg, W. D. (2021). Anti-tumor activity of NLG207 (formerly CRLX101) in combination with enzalutamide in preclinical prostate cancer models. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.MCT-20-0228 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress

The authors sensitized androgen-independent and TRAIL-resistant prostate cancer cells to TRAIL-mediated apoptosis via taxane therapy and examined the mechanism of sensitization.
[Molecular Cancer Therapeutics]
Grayson, K. A., Hope, J. M., Wang, W., Reinhart-King, C. A., & King, M. R. (2021). Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.MCT-20-0495 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Disulfiram-Copper Activates Chloride Currents and Induces Apoptosis with Tyrosine Kinase in Prostate Cancer Cells

Scientists elucidated the mechanism that disulfiram/copper complex treatment activated chloride channels and induced apoptosis in prostate cancer cells.
[Asia-Pacific Journal of Clinical Oncology]
Lei, W., Xu, J., Ya, Y., Zhang, J., Hou, X., Zhai, Q., Zha, Z., Zhuo, Y., Zhou, Y., Yuan, H., Liang, Y., Han, Z., Zhong, W., Zhu, L., & Chen, Y. (n.d.). Disulfiram-copper activates chloride currents and induces apoptosis with tyrosine kinase in prostate cancer cells. Asia-Pacific Journal of Clinical Oncology, n/a(n/a). https://doi.org/https://doi.org/10.1111/ajco.13551 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Discovery of a Novel AR/HDAC6 Dual Inhibitor for Prostate Cancer Treatment

Given that both androgen receptor (AR) antagonists and histone deacetylase 6 (HDAC6) inhibitors modulate AR signaling, a novel AR/HDAC6 dual inhibitor was investigated for its anticancer effects in castration-resistant prostate cancer.
[Aging]
Aging | Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment - Full Text. (n.d.). Retrieved February 26, 2021, from https://www.aging-us.com/article/202554/text Cite
Abstract
Bookmark

No account yet? Register

0
Share

The Role of Opiorphin Genes in Prostate Cancer Growth and Progression

Researchers investigated a role for opiorphin genes in prostate cancer (PrCa). Databases and PrCa tissue arrays were screened for opiorphin expression.
[Future Oncology]
Mukherjee, A., Park, A., Wang, L., & Davies, K. P. (2021). The role of opiorphin genes in prostate cancer growth and progression. Future Oncology. https://doi.org/10.2217/fon-2020-1299 Cite
Abstract
Bookmark

No account yet? Register

0
Share

ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma, Inc. announced that the company has entered into a clinical collaboration and supply agreement with Astellas Pharma, Inc. to evaluate ESSA’s lead product candidate, EPI-7386, in combination with Astellas and Pfizer Inc.’s androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer.
[ESSA Pharma, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

CPDC Announces First Patient Dosed in a Phase III Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Centre for Probe Development and Commercialization (CPDC) announced that the first patient has been dosed and imaged in a Phase III trial for [18F]Prostate Specific Membrane Antigen (PSMA)-1007. This diagnostic imaging product is a positron-emitting tomography agent that targets PSMA, a protein that is overexpressed in prostate cancer.
[Centre for Probe Development and Commercialization]
Press Release
Bookmark

No account yet? Register

0
Share

Specific Detection of Prostate Cancer Cells in Urine by RNA in Situ Hybridization

The authors investigated application of the RNA in situ hybridization assay for prostate cancer detection in a cohort of 98 patients suspected of harboring prostate cancer.
[Journal of Urology]
Eskra Jillian N., Rabizadeh Daniel, Zhang Jiayi, Isaacs William B., Luo Jun, & Pavlovich Christian P. (n.d.). Specific Detection of Prostate Cancer Cells in Urine by RNA in Situ Hybridization. Journal of Urology, 0(0), 10.1097/JU.0000000000001691. https://doi.org/10.1097/JU.0000000000001691 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Upregulation of Glucocorticoid Receptor-Mediated Glucose Transporter 4 in Enzalutamide-Resistant Prostate Cancer

Inhibition of glucocorticoid receptor‐mediated glucose transporter 4 suppressed cell proliferation in enzalutamide (Enz)‐resistant prostate cancer cells, which recovered from Enz resistance and cross‐resistance without changes in glucocorticoid receptor expression.
[Cancer Science]
Hoshi, S., Meguro, S., Imai, H., Matsuoka, Y., Yoshida, Y., Onagi, A., Tanji, R., Honda‐Takinami, R., Matsuoka, K., Koguchi, T., Hata, J., Sato, Y., Akaihata, H., Kataoka, M., Ogawa, S., & Kojima, Y. (n.d.). Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. Cancer Science, n/a(n/a). https://doi.org/https://doi.org/10.1111/cas.14865 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share